Get the Stockscreener App
0.25
0.71%
-0.0018
After Hours:
.26
0.01
+4.00%
Rallybio Corp stock is traded at $0.25, with a volume of 27,778.
It is down -0.71% in the last 24 hours and down -61.07% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.2518
Open:
$0.2442
24h Volume:
27,778
Relative Volume:
0.29
Market Cap:
$11.24M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.1365
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
-0.24%
1M Performance:
-61.07%
6M Performance:
-77.06%
1Y Performance:
-85.80%
1-Day Range:
$0.2439
$0.2593
1-Week Range:
$0.2235
$0.276
52-Week Range:
$0.2201
$2.00
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.25 | 11.24M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Rallybio to Neutral From Buy - MarketScreener
Rallybio sinks as it drops RLYB212 for prevention of FNAIT - The Pharma Letter
Rallybio ends RLYB212 program after trial setback - Investing.com Australia
Citizens JMP cuts Rallybio stock rating following program halt By Investing.com - Investing.com Canada
Rallybio stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Citizens JMP cuts Rallybio stock rating following program halt - Investing.com Australia
Rallybio stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Rallybio Corporation to Discontinue Development of RLYB212 for Prevention of FNAIT - MarketScreener
Citizens JMP downgrades Rallybio on RLYB212 discontinuation - TipRanks
Rallybio pulls plug on rare pregnancy blood disorder treatment - FirstWord Pharma
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
Rallybio discontinues lead drug for rare maternal disorder - BioPharma Dive
Rallybio Pivots as Antibody for Rare Bleeding Disorder Flunks Dosing Trial - BioSpace
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
New Haven-based Rallybio discontinues development of rare disease therapy - Hartford Business Journal
Rallybio shares tumble 36% after RLYB212 program halt By Investing.com - Investing.com South Africa
Rallybio shares tumble 36% after RLYB212 program halt - Investing.com India
Rallybio Corp Discontinues Rlyb212 Program For Prevention Of Fnait - MarketScreener
Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint - Fierce Biotech
Rallybio ends RLYB212 program after trial setback By Investing.com - Investing.com India
Rallybio discontinues RLYB212 program - TipRanks
Major Pipeline Shift: Rallybio Abandons FNAIT Drug to Target Lucrative $6B Disease Market - Stock Titan
Rallybio stock plunges to 52-week low, hitting $0.6 - Investing.com Australia
Rallybio stock plunges to 52-week low, hitting $0.6 By Investing.com - Investing.com India
Rallybio stock plunges to 52-week low at $0.62 amid market challenges - Investing.com Canada
Rallybio stock plunges to 52-week low at $0.62 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Issues Positive Estimate for Rallybio Earnings - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Rallybio (NASDAQ:RLYB) Receives “Buy” Rating from HC Wainwright - Defense World
Rallybio’s Promising Developments and Financial Stability Justify Buy Rating - TipRanks
Rallybio Corporation (NASDAQ:RLYB) Is Expected To Breakeven In The Near Future - Simply Wall St
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating - TipRanks
Rallybio Corporation Reports 2024 Financial Results and Progress - TipRanks
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):